Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry
Authors:
- Lara S. van der SchootLSLara S. van der Schoot
- Hans J. M. M. GroenewoudHGHans J. M. M. Groenewoud
- Marleen M. H. J. van GelderMGMarleen M. H. J. van Gelder
- Marisol E. OteroMOMarisol E. Otero
- W. Peter ArnoldWAW. Peter Arnold
- Maartje A. M. BerendsMBMaartje A. M. Berends
- Marjolein S. De Bruin‐WellerMBMarjolein S. De Bruin‐Weller
- Sharon R. P. DodemontSDSharon R. P. Dodemont
- Marjolein I. A. KoetsierMKMarjolein I. A. Koetsier
- Else N. KopEKElse N. Kop
- John E. M. KörverJKJohn E. M. Körver
Open Access
- 24 June 2022
- journal article
- research article
- Published by Wiley in JEADV Clinical Practice
- Vol. 1 (3) , 240-253
Abstract
Background: Limited real‐world studies are available comparing infection risk between biologics for psoriasis.Objectives: The primary aim was to determine the differential effect of currently available biologics on the risk of respiratory tract infections (RTI) among psoriasis patients in a real‐world setting. Secondary aims were to explore the differential risk of all types of serious infections (SI) between biologics and to provide an early overview of SARS‐CoV‐2 infections during the pre‐vaccine era.Methods: Crude incidence rates of RTI and SI were calculated per 100 patient‐years (PY) per biologic using prospective BioCAPTURE data. Negative Binomial Regression modeling was used to explore the risk of RTI. Frailty Cox proportional hazards modeling was used to estimate hazard ratios for the risk of the first SI. Confounders adjusted for both models were selected by a directed acyclic graph. A post hoc exploratory analysis of SARS‐CoV‐2 infection incidence rates during 2020 was performed.Results: We included 714 patients with 1325 treatment episodes (3607.7PY between 2005 and 2020), in which 2224 RTI and 63 SI occurred. Among RTI, 1.3% were serious. The crude incidence rates were 61.7 (95% confidence interval [CI]: 59.1–64.3) per 100PY for RTI, and 1.8 (95% CI: 1.4–2.2) per 100PY for SI. Confounder adjusted analyses showed no differential risk of RTI between adalimumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab and guselkumab. For SI, no differential risk was found between biologics either. Extended single‐center data showed 3.8 (95% CI: 2.2–6.1) SARS‐CoV‐2 infections per 100PY in 2020.Conclusions: Confounder adjusted analyses showed no differential risks of RTI or SI between included biologics (adalimumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab and guselkumab) in a prospective psoriasis patients cohort. In general, absolute numbers of all types of SI were low.Keywords
Funding Information
- Pfizer
- Janssen Pharmaceutica
- LEO Pharma Research Foundation
- AbbVie
- Novartis
This publication has 43 references indexed in Scilit:
- Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBestArchives of Dermatological Research, 2015
- Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisJournal of the American Academy of Dermatology, 2015
- Risk of Serious Infection With Biologic and Systemic Treatment of PsoriasisJAMA Dermatology, 2015
- ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTUREnetworkBritish Journal of Dermatology, 2014
- Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registryJournal of the European Academy of Dermatology and Venereology, 2014
- Distribution‐free models for longitudinal count responses with overdispersion and structural zerosStatistics in Medicine, 2012
- The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trialsJournal of the American Academy of Dermatology, 2011
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBritish Journal of Dermatology, 2005
- Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17Journal of Biological Chemistry, 2003